Detailed data from the trial was presented at the American Society of Clinical Oncology meeting in Chicago on Sunday. Treatments for multiple myeloma include Johnson & Johnson's JNJ.N Darzalex and other generic cancer drugs. The US FDA in April approved two cell therapies - J&J's Carvykti, and Bristol Myers' Abecma - as earlier lines of treatment in less severe multiple myeloma. Multiple myeloma, the world's second-most common blood cancer, starts in plasma cells in bone marrow and ultimately disrupts production of normal blood cells. Roughly 35,780 new multiple myeloma cases are likely to be diagnosed, with 12,540 deaths expected to occur in the United States this year, according to the American Cancer Society.
